Introduction and Aim: The purpose of this meta-analysis was to evaluate the efficacy of antimuscarinics alone or in combination with alpha-blockers for the treatment of ureteral stent-related symptoms. Methods: The databases MEDLINE, EMBASE, PubMed, the Cochrane Controlled Trial Register of Controlled Trials from 2000 to February 2016 were searched to identify randomized controlled trials that referred to the use of a combination of antimuscarinics and alpha-blockers for the treatment of ureteral stent-related symptoms. A systematic review and meta-analysis was conducted. Results: Seven publications involving 710 patients were included in the meta-analysis. In the analysis, we found significantly improved total International Prostate Symptom Score, quality of life, body pain and work performance score of the Ureteral Stent Symptom Questionnaire (USSQ) in the combination group compared with antimuscarinics alone (p = 0.00001, p = 0.00001, p = 0.00001 and p = 0.004, respectively). Antimuscarinics alone versus the control group showed significant improvement in urinary symptom, body pain and general health score of USSQ (p = 0.002, p = 0.00001 and p = 0.003, respectively). Conclusions: Our meta-analysis shows the beneficial effect of antimuscarinics alone in reducing stent-related symptoms. The combined use of antimuscarinics and alpha-blockers results in additive favorable effects in patients with ureteral stent-related symptoms compared with antimuscarinics monotherapy. The alpha-blockers may enhance the efficacy of the antimuscarinics, which is beneficial for the treatment of ureteral stent-related symptoms.

Keywords:
Antimuscarinics, Alpha-blockers, Ureteral stent-related symptoms, Meta-analysis, Randomized controlled trials
1.
Zimskind PD, Fetter TR, Wilkerson JL: Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967;97:840-844.
2.
Chew BH, Knudsen BE, Denstedt JD: The use of stents in contemporary urology. Curr Opin Urol 2004;14:111-115.
3.
Haleblian G, Kijvikai K, de la Rosette J, Preminger G: Ureteral stenting and urinary stone management: a systematic review. J Urol 2008;179:424-430.
4.
Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ: Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003;169:1065-1069; discussion 1069.
5.
Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG: Characterization of urinary symptoms in patients with ureteral stents. Urology 2002;59:511-516.
6.
Siggers JH, Waters S, Wattis J, Cummings L: Flow dynamics in a stented ureter. Math Med Biol 2009;26:1-24.
7.
Sameh WM, Eid AA: Pressure transmission through ureteric stents: a novel in vivo human study. Urology 2012;79:766-770.
8.
Camões J, Coelho A, Castro-Diaz D, Cruz F: Lower urinary tract symptoms and aging: the impact of chronic bladder ischemia on overactive bladder syndrome. Urol Int 2015;95:373-379.
9.
Dellis A, Joshi HB, Timoney AG, Keeley FX Jr: Relief of stent related symptoms: review of engineering and pharmacological solutions. J Urol 2010;184:1267-1272.
10.
Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ: Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int 2011;108:1894-1902.
11.
Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P: Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 2011;186:928-934.
12.
Zhou L, Cai X, Li H, Wang KJ: Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol 2015;29:650-656.
13.
Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG: Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 2003;169:1060.
14.
Higgins JP, Green S: Cochrane handbook for systematic reviews of interventions, v.5.1. Cochrane Collaboration Web site 2011. http://www.cochrane-handbook.org (updated March 2011).
15.
Lim KT, Kim YT, Lee TY, Park SY: Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol 2011;52:485-488.
16.
Shalaby E, Ahmed AF, Maarouf A, Yahia I, Ali M, Ghobish A: Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-J stent-related lower urinary symptoms. Adv Urol 2013;2013:752382.
17.
Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M: Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol 2013;39:832-840.
18.
Park J, Yoo C, Han DH, Shin DW: A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial. World J Urol 2015;33:1833-1840.
19.
Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK: Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 2013;41:247-252.
20.
El-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA: A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol 2016;34:963-968.
21.
Abdelaal AM, Al-Adl AM, Abdelbaki SA, Al Azab MM, Al Gamal KA: Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms. Arab J Urol 2016;14:115-122.
22.
Damiano R, Oliva A, Esposito C, De Sio M, Autorino R, D'Armiento M: Early and late complications of double pigtail ureteral stent. Urol Int 2002;69:136-140.
23.
Dunn MD, Portis AJ, Kahn SA, Yan Y, Shalhav AL, Elbahnasy AM, et al: Clinical effectiveness of new stent design: randomized single-blind comparison of tail and double-pigtail stents. J Endourol 2000;14:195-202.
24.
Ho CH, Chen SC, Chung SD, Lee YJ, Chen J, Yu HJ, et al: Determining the appropriate length of a double-pigtail ureteral stent by both stent configurations and related symptoms. J Endourol 2008;22:1427-1431.
25.
Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M: Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 2008;22:651-656.
26.
Park SC, Jung SW, Lee JW, Rim JS: The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms. J Endourol 2009;23:1913-1917.
27.
Madersbacher S, Marszalek M, Lackner J, Berger P, et al: The long-term outcome of medical therapy for BPH. Eur Urol 2007;51:1522-1533.
28.
White N, Iglesia CB: Overactive bladder. Obstet Gynecol Clin North Am 2016;43:59-68.
29.
Wang CJ, Huang SW, Chang CH: Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 2009;37:147-152.
30.
Staubli SE, Mordasini L, Engeler DS, Sauter R, Schmid HP, Abt D: Economic aspects of morbidity caused by ureteral stents. Urol Int 2016;97:91-97.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.